Kevin Outterson, JD, LLM

Professor Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the founding Executive Director and Principal Investigator for CARB-X, an >$800M international public-private partnership to accelerate global antibacterial innovation. Key partners of CARB-X include the US Government – Biomedical Advanced Research and Development Authority (BARDA) and U.S. National Institute of Allergy and Infectious Diseases (NIAID) – Wellcome, the U.K. and German governments (the Global AMR Innovation Fund and the Federal Ministry of Education and Research), and the Bill & Melinda Gates Foundation.  

Professor Outterson’s research focuses on the law and economics of antimicrobial resistance, particularly push and pull incentives for antimicrobials. He has served as a senior author on many key research reports on antibiotic innovation, including Chatham House, ERG, DRIVE-AB, and the Lancet Commission. Professor Outterson received the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before the US Congress, UK Parliamentary working groups, the World Health Organization (WHO), and state legislatures. In 2022, the Council of Canadian Academies appointed him to an expert panel on antimicrobial pull incentives. Since August 2016, he has led CARB-X, the world’s most innovative antibiotic accelerator.